Photo taken from: Kiran Patel / LinkedIn
Jul 18, 2023, 05:37
Positive topline results from the Phase 3 PAPILLON study in patients with non-small cell lung cancer – Kiran Patel
Today, The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from the Phase 3 PAPILLON study in patients with non-small cell lung cancer (NSCLC) characterized by specific genetic alterations.
We’re advancing the science of lung cancer through the development of targeted therapies for patients with genetically-defined NSCLC who often experience poor prognoses and shorter survival.
We remain focused on bringing forward transformative treatment options to reduce the impact of the world’s leading cause of cancer mortality.
Read more about these results: https://bit.ly/3JXLh5l
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 28, 2025, 18:34
Feb 28, 2025, 15:34
Feb 28, 2025, 15:33
Feb 28, 2025, 15:25
Feb 28, 2025, 15:22
Feb 28, 2025, 15:20
Feb 28, 2025, 15:13
Feb 28, 2025, 15:02
Feb 28, 2025, 14:43
Feb 28, 2025, 14:37